620
Views
13
CrossRef citations to date
0
Altmetric
Clinical Features - Review

Transdermal estrogens in the changing landscape of hormone replacement therapy

, &
Pages 632-636 | Received 10 Apr 2017, Accepted 22 May 2017, Published online: 31 May 2017

References

  • Ettinger B, Wang SM, Leslie RS, et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause. 2012;19:610–615.
  • Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47–53.
  • Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016–1037.
  • Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333.
  • Stampfer MJ, Willett WC, Coldiz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044–1049.
  • Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312–317.
  • Humphrey LL, Benjamin KS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273–284.
  • Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up in (HERS II). JAMA. 2002;288:49–57.
  • Grodstein F, Stampfer MJ, Manson JE, et al. Post-menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461.
  • Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712.
  • Haas JS, Kaplan CP, Gerstenberger EP, et al. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140:184–188.
  • Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health Initiative. JAMA. 2004;292:1983–1988.
  • Stephenson J. FDA orders estrogen safety warnings: agency offers guidelines for HRT use. JAMA. 2003;289:537–538.
  • ACOG Task Force on Hormone Therapy. Hormone therapy. Obstet Gynecol. 2004;104:1s–131s.
  • Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Women’s Health. 2012;21:161–169.
  • Stuenkel CA. Menopausal hormone therapy. Endocrin Metab Clin N Am. 2015;44:565–585.
  • ACOG practice bulletin number 141. Management of menopausal symptoms. Obstet Gynecol. 2014;123:202–216.
  • Baber RJ, Panay N, Fenton A. The IMS Writing Group, 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150.
  • Gleason CE, Carlsson CM, Johnson S, et al. Clinical pharmacology and differential cognitive efficacy of estrogen preparations. Ann NY Acad Sci. 2005;1052:93–115.
  • Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels: matrix versus reservoir patches. Gynecol Endocrinol. 1993;7:251–258.
  • Margarido PF, Bagnoli VR, Maggio Da Fonseca A, et al. Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study. Cin Exp Obstet Gynecol. 2011;38:232–235.
  • Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003;23:1116–1121.
  • Bonduki CE, Lourenco DM, Motta EL, et al. Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women. Clinics (Sao Paulo). 2007;62:553–560.
  • Mohammed K, Moain A, Dabrh A, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:4012–4020.
  • Corbelli H, Shaikh N, Wessel C, et al. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2015;22:114–121.
  • Liu B. Is transdermal menopausal hormone therapy a safer option than oral therapy? Cmaj. 2013;185:549–550.
  • Kapp N. WHO provider brief on hormonal contraception and liver disease. Contraception. 2009 [Accessed May 152017.];80:325–326.
  • Samsioe G. Transdermal hormone therapy; gels and patches. Climacteric. 2004;7:347–356.
  • Musel AL, Warshaw EM. Cutaneous reactions to transdermal therapeutic systems. Dermatitis. 2006;17:109–122.
  • Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8:3–63.
  • Erianne JA, Winter L Jr. Comparison of local tolerability and adhesion of a new matrix system (Menorest) for estradiol delivery with and established transdermal membrane systems (Estraderm TTS). Maturitas. 1997;26:95–101.
  • Reginster JY, Donazzolo Y, Brion N, et al. Estradiol pharmacokinetics after transdermal application of patches to post-menopausal women: matrix versus reservoir patches. Climacteric. 2000;3:168–175.
  • Munoz A. Oesclim: an advanced delivery system for HRT. Maturitas. 1999;33:S39–S47.
  • Rozenbaum H, Birkhauser M, De Nooyer C, et al. Comparison of two estradiol transdermal Systems (Oesclim 50 and Estraderm TTS 50). Tolerability, adhesion and efficacy. Maturitas. 1996;25:161–173.
  • Kopper NW, Gudeman J, Thompson DJ. Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. Drug Des Devel Ther. 2009;2:193–202.
  • Abdi F, Mobedi H, Mosaffa N, et al. Hormone therapy for relieving postmenopausal vasomotor symptoms: a systematic review. Arch Iranian Med. 2016;19:141–146.
  • Paudel KS, Milewksi M, Swadley CL, et al. Challenges and opportunities in dermal/transdermal delivery. Ther Deliver. 2010;1:109–131.
  • Pharmacist Letter. Postmenopausal hormone therapy. Stockton, CA: Therapeutic Research Center. March, 2014.
  • Estradiol. Index Nominum. 2014;1:717–723. Accessed March 3, 2017.
  • Moyer V. On behalf of the US Preventative Task Force, Menopausal hormone therapy for the prevention of chronic conditions: US preventative task force recommendation statement. Ann Intern Med. 2013;158:47–54.
  • O’Connor L. NAMS hormone therapy position statement. OBG Management. 2016;28:10.
  • Lambrinoudaki I, Brincat M, Tamer Erel C, et al. EMAS position statement: managing obese postmenopausal women. Maturitas. 2010;66:323–326.
  • Brennan JJ, Lu Z, Whtiman M, et al. Gerritsen van der Hoop R. Serum concentration of 17-estradio and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women. Ther Drug Monit. 2001;23:134–138.
  • Natchtigall LE. Emerging delivery systems for estrogen replacement. Aspects of transdermal and oral delivery. Am J Obstet Gynecol. 1995;173:993–997.
  • Baracat EC, Simoes MJ, Soares JM Jr, et al. Rodrigues de Lima G. Ultrastructural aspects of the postmenopausal endometrium after oral or transdermal estrogen administration. Clin Exp Obstet Gynecol. 2001;28:26–30.
  • L’hermite M, Simoncini T, Fuller S, et al. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas. 2008;60:185–201.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.